REGENXBIO (NASDAQ:RGNX) Upgraded by StockNews.com to “Hold” Rating

StockNews.com upgraded shares of REGENXBIO (NASDAQ:RGNX) from a sell rating to a hold rating in a report issued on Friday.

Other analysts have also issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of REGENXBIO in a research note on Wednesday, January 15th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. Morgan Stanley restated an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th. Chardan Capital reaffirmed a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday, November 20th. Finally, Raymond James started coverage on shares of REGENXBIO in a research note on Friday. They issued an “outperform” rating and a $27.00 target price on the stock. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.64.

REGENXBIO Trading Down 2.6 %

REGENXBIO stock opened at $8.21 on Friday. The firm has a 50 day simple moving average of $8.11 and a 200 day simple moving average of $10.10. REGENXBIO has a 1-year low of $6.56 and a 1-year high of $28.80.

Institutional Trading of REGENXBIO

Hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in shares of REGENXBIO in the fourth quarter worth about $568,000. Y Intercept Hong Kong Ltd purchased a new position in REGENXBIO in the 4th quarter worth approximately $1,062,000. Hennion & Walsh Asset Management Inc. lifted its position in REGENXBIO by 8.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company’s stock valued at $1,273,000 after purchasing an additional 13,014 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of REGENXBIO by 53.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after purchasing an additional 296,700 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,510 shares during the last quarter. 88.08% of the stock is owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.